VAGELOS P ROY - 16 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**P. Roy Vagelos
Issuer symbol
REGN
Transactions as of
16 Dec 2022
Net transactions value
$0
Form type
4
Filing time
20 Dec 2022, 16:44:48 UTC
Previous filing
13 Dec 2022
Next filing
21 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Award $0 +1,651 +0.51% $0.000000 324,083 16 Dec 2022 Direct F1
holding REGN Common Stock 2,102 16 Dec 2022 By 401(k) Plan
holding REGN Common Stock 126,043 16 Dec 2022 by CLAT
holding REGN Common Stock 23,461 16 Dec 2022 by Spouse as Trustee
holding REGN Common Stock 3,609 16 Dec 2022 by trust for grandch F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +16,254 $0.000000 16,254 16 Dec 2022 Common Stock 16,254 $726.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock.
F2 By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
F3 The stock option award vests in four equal annual installments, commencing one year after the date of grant.